Inhibiting the GLS1 enzyme could improve numerous age-associated disorders, finds study
In a new study, inhibitors of the GLS1 enzyme caused the death of senescent cells and relieved the symptoms of various age-related diseases in mice.
List view / Grid view
In a new study, inhibitors of the GLS1 enzyme caused the death of senescent cells and relieved the symptoms of various age-related diseases in mice.
Researchers have found a druggable insulin inhibitory receptor named inceptor that could provide a drug target for diabetes.
Researchers have identified a new compound that improved responses to insulin and treated diabetes in obese mouse models.
Researchers have identified microbes that could affect the way a person metabolises glucose and lipids, leading to a potential treatment for type 2 diabetes.
Anthony Finbow explains how applying microbiome-based evidence to disease modelling will enable researchers to devise more targeted treatments.
Researchers have developed a novel insulin molecule that responds to glucose levels in the blood sugar of rats, which they say could help patients with type 1 diabetes.
Recent reports suggest that both clinical and genetic risk factors may contribute to COVID-19 susceptibility and severity. Catherine Ball, Chief Scientific Officer of Ancestry®, discusses results of the company’s COVID-19 Research Study, designed to explore non-genetic and genetic associations with disease outcomes.
Researchers have shown that the internal clock controls the regenerative mechanism behind beta cells in diabetic mice.
An engineered form of the SMOC1 protein has shown success as a type 2 diabetes treatment in animal models, say researchers.
The developers of a temporary coating which adheres to the small intestine demonstrated it could be modified to deliver drugs, aid digestion and stop absorption of glucose.
A study in older mice with type 2 diabetes revealed a tuberculosis vaccine elicited a strong immune response, making it a promising candidate for the condition.
A study has shown that SRI-37330 is successful at improving the characteristics of diabetes in human pancreatic islets and animal models.
The novel formulation hit peak activity at nine minutes, less than half the time taken for a commercially available formulation.
Two molecules combined into a new substance to treat type 2 diabetes lowered blood sugar in shrew models without causing nausea, vomiting and weight loss.
New research indicates COVID-19 could trigger the development of diabetes in healthy people, prompting experts to establish a registry for COVID-19 and diabetes data.